Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Research Article

Ultra-Performance Liquid Chromatography Coupled with a Triple Quadrupole Mass Spectrometric Method for the Quantification of Antiepileptic Drugs Methsuximide and Normesuximide in Human Plasma and its Application in a Pharmacokinetic Study

Author(s): Karthik Rajendran, Karthika Anoop, Krishnaveni Nagappan*, Genguchetti Mohan Sekar and Sankham Devendran Rajendran

Volume 18, Issue 2, 2022

Published on: 11 February, 2021

Page: [228 - 239] Pages: 12

DOI: 10.2174/1573412917666210211122311

Abstract

Background: Extensive therapeutic drug monitoring needs an analytical method for efficient and sensitive quantification of analytes of interest in clinical pharmacology.

Objectives: A rapid, robust, sensitive and simple UPLC-MS/MS method to quantify Methsuximide (Ms) and N-desmethyl methsuximide/Normesuximide (MsMET) in human plasma was optimized, developed, and validated for application in a pharmacokinetic study.

Methods: Reverse phased chromatography was performed using Zorbax SB-C18, 4.6 x 75 mm., 3.5 μm as stationary phase, methanol and 0.1% formic acid (60:40 v/v) as mobile phase which was delivered isocratically at a flow rate of 0.9 mL/min. The sample injection volume was 5 μL. Mass spectrometric quantification of the analytes was performed using positive electrospray ionization as mass interface along with multiple reaction monitoring (MRM) as acquisition mode.

Results: The selected mass transition ions for analyte, metabolite and its respective internal standards are as follows, precursor ion (m/z) and product ion (m/z): Ms (204.06 and 119.02), MsMET (190.05 and 119.82), Ms internal standard (MsIS) (209.17 and 124.02), and MsMET internal standard (MsMETIS) (195.09 and 124.16), respectively. The current method was found to be linear for Ms (60.720-6043.800 ng/mL) and MsMET (60.389 - 6010.800 ng/mL) with r2 values not less than 0.999. The mean recoveries of all analytes ranged between 71.37 and 86.38 percentage. Conclusion: This method was validated in accordance with USFDA’s bioanalytical guidelines.

This method could be applied for a routine analysis of Ms and MsMET in clinical pharmacological practice.

Keywords: Bioanalytical, methsuximide, N-desmethyl methsuximide, UPLC-MS/MS, validation, calcium.

Graphical Abstract
[1]
Jacob, S.; Nair, A.B. An updated overview on therapeutic drug monitoring of recent antiepileptic drugs. Drugs R D., 2016, 16(4), 303-316.
[http://dx.doi.org/10.1007/s40268-016-0148-6] [PMID: 27766590]
[2]
Marvanova, M. Pharmacokinetic characteristics of antiepileptic drugs (AEDs). Ment Health Clin, 2016, 6(1), 8-20.
[http://dx.doi.org/10.9740/mhc.2015.01.008] [PMID: 29955442]
[3]
Petkovic-Cvetkovic, J.; Bozic, B.; Banjac, N.; Ladjarevic, J.; Vitnik, V.; Vitnik, Z.; Valentic, N.; Uscumlic, G. Spectroscopic and quantum chemical elucidation of newly synthesized 1-aryl-3-methyl-3-phenylpyrrolidine-2,5-diones as potentional anticonvulsant agents. Hem. Ind., 2019, 73(2), 125-137.
[http://dx.doi.org/10.2298/HEMIND190214011P]
[4]
Patsalos, P.N. Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia, 2005, 46(Suppl. 9), 140-148.
[http://dx.doi.org/10.1111/j.1528-1167.2005.00326.x] [PMID: 16302888]
[5]
Porter, R.J.; Penry, J.K.; Lacy, J.R.; Newmark, M.E.; Kupferberg, H.J. Plasma concentrations of phensuximide, methsuximide, and their metabolites in relation to clinical efficacy. Neurology, 1979, 29(11), 1509-1513.
[http://dx.doi.org/10.1212/WNL.29.11.1509] [PMID: 116142]
[6]
Tennison, M.B.; Greenwood, R.S.; Miles, M.V. Methsuximide for intractable childhood seizures. Pediatrics, 1991, 87(2), 186-189.
[PMID: 1987529]
[7]
Asif, M. A review on antiepileptic drug and their uses, mechanism of actions, adverse effects and drug interaction. Current Science Perspectives, 2016, 2(2), 19-38.
[8]
Dasgupta, A., Ed.; Advances in Chromatographic Techniques for Therapeutic Drug Monitoring; CRC Press, 2009.
[9]
Wad, N.; Bourgeois, B.; Krämer, G. Serum protein binding of desmethyl-methsuximide. Clin. Neuropharmacol., 1999, 22(4), 239-240.
[PMID: 10442255]
[10]
Battino, D.; Estienne, M.; Avanzini, G. Clinical pharmacokinetics of antiepileptic drugs in pediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Clin. Pharmacokinet., 1995, 29(4), 257-286.
[http://dx.doi.org/10.2165/00003088-199529040-00005] [PMID: 8549027]
[11]
Miles, M.V.; Tennison, M.B.; Greenwood, R.S. Pharmacokinetics of N-desmethylmethsuximide in pediatric patients. J. Pediatr., 1989, 114(4 Pt 1), 647-650.
[http://dx.doi.org/10.1016/S0022-3476(89)80714-0] [PMID: 2926578]
[12]
Hiemke, C.; Bergemann, N.; Clement, H.; Conca, A.; Deckert, J.; Domschke, K.; Eckermann, G.; Egberts, K.; Gerlach, M.; Greiner, C.; Gründer, G.; Haen, E.; Havemann-Reinecke, U.; Hefner, G.; Helmer, R.; Janssen, G.; Jaquenoud, E.; Laux, G.; Messer, T.; Mössner, R.; Müller, M.; Paulzen, M.; Pfuhlmann, B.; Riederer, P.; Saria, A.; Schoppek, B.; Schoretsanitis, G.; Schwarz, M.; Gracia, M.; Stegmann, B.; Steimer, W.; Stingl, J.; Uhr, M.; Ulrich, S.; Unterecker, S.; Waschgler, R.; Zernig, G.; Zurek, G.; Baumann, P. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry, 2017, 51(01/02), 9-62.
[http://dx.doi.org/10.1055/s-0043-116492]
[13]
Brandt, C.; Baumann, P.; Eckermann, G.; Hiemke, C.; May, T.W.; Rambeck, B.; Pohlmann-Eden, B. [Therapeutic drug monitoring in epileptology and psychiatry] Nervenarzt, 2008, 79(2), 167-174.
[http://dx.doi.org/10.1007/s00115-007-2325-x] [PMID: 17701390]
[14]
Huisman, J.W. The estimation of some important anticonvulsant drugs in serum. Clin. Chim. Acta, 1966, 13(3), 323-328.
[http://dx.doi.org/10.1016/0009-8981(66)90211-7] [PMID: 5943824]
[15]
Turczan, J.W.; Goldwitz, B.A. NMR analysis of pharmaceuticals. X. Determination of methsuximide and phensuximide in capsules. J. Pharm. Sci., 1973, 62(10), 1705-1707.
[http://dx.doi.org/10.1002/jps.2600621030] [PMID: 4752119]
[16]
Muni, I.A.; Altshuler, C.H.; Neicheril, J.C. Identification of a blood metabolite of methsuximide by GLC-mass spectrometry. J. Pharm. Sci., 1973, 62(11), 1820-1823.
[http://dx.doi.org/10.1002/jps.2600621117] [PMID: 4758080]
[17]
Dobrinska, M.R.; Welling, P.G. Pharmacokinetics of methsuximide and a major metabolite in dogs. J. Pharm. Sci., 1977, 66(5), 688-692.
[http://dx.doi.org/10.1002/jps.2600660520] [PMID: 577506]
[18]
Ritz, D.P.; Gerald Warren, C.; Teitelbaum, D.T. Single extraction GLC analysis of six commonly prescribed antiepileptic drugs. Clin. Toxicol., 1975, 8(3), 311-324.
[http://dx.doi.org/10.3109/15563657508988080] [PMID: 1175347]
[19]
Watson, J.R.; Lawrence, R.C.; Lovering, E.G. Simple GLC analysis of anticonvulsant drugs in commercial dosage forms. J. Pharm. Sci., 1978, 67(7), 950-953.
[http://dx.doi.org/10.1002/jps.2600670720] [PMID: 26793]
[20]
Wallace, J.E.; Schwertner, H.A.; Hamilton, H.E.; Shimek, E.L., Jr Electron-capture gas-liquid chromatographic determination of ethosuximide and desmethylmethsuximide in plasma or serum. Clin. Chem., 1979, 25(2), 252-255.
[http://dx.doi.org/10.1093/clinchem/25.2.252] [PMID: 581562]
[21]
Riedmann, M.; Rambeck, B.; Meijer, J.W.A. Quantitative simultaneous determination of eight common antiepileptic drugs and metabolites by liquid chromatography. Ther. Drug Monit., 1981, 3(4), 397-413.
[http://dx.doi.org/10.1097/00007691-198104000-00010] [PMID: 6895956]
[22]
Neels, H.M.; Totté, J.A.; Verkerk, R.M.; Vlietinck, A.J.; Scharpé, S.L. Simultaneous high performance liquid-chromatographic determination of carbamazepine, carbamazepine-10,11-epoxide, ethosuximide, phenobarbital, phenytoin, primidone and phenylethylmalonamide in plasma. J. Clin. Chem. Clin. Biochem., 1983, 21(5), 295-299.
[http://dx.doi.org/10.1515/cclm.1983.21.5.295] [PMID: 6875477]
[23]
Cardella, D.S.; Levtzow, C.B.; Rifai, N.; Cross, R.E.; Howlett, C.M.; Parker, N.C. Measurement of methsuximide and N-desmethylmethsuximide using solid-phase extraction and wide-bore capillary gas chromatography. Clin. Biochem., 1988, 21(6), 329-331.
[http://dx.doi.org/10.1016/S0009-9120(88)80012-2] [PMID: 3233745]
[24]
Miles, M.V.; Howlett, C.M.; Tennison, M.B.; Greenwood, R.S.; Cross, R.E. Determination of N-desmethylmethsuximide serum concentrations using enzyme-multiplied and fluorescence polarization immunoassays. Ther. Drug Monit., 1989, 11(3), 337-342.
[http://dx.doi.org/10.1097/00007691-198905000-00018] [PMID: 2658212]
[25]
Streete, J.M.; Berry, D.J.; Clarke, L.A.; Newbery, J.E. Analysis of desmethylmethsuximide using high-performance liquid chromatography. Ther. Drug Monit., 1995, 17(3), 280-286.
[http://dx.doi.org/10.1097/00007691-199506000-00012] [PMID: 7624925]
[26]
Chollet, D.F. Determination of antiepileptic drugs in biological material. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2002, 767(2), 191-233.
[http://dx.doi.org/10.1016/S0378-4347(01)00502-3] [PMID: 11885851]
[27]
ANTIEPILEPTICS in Plasma by LC-MS - Deuterated Internal Std - Code LC05015. 2016.
[28]
ANTIEPILEPTICS in Plasma by LC-MS - Deuterated Internal Std - Code LC05010. 2017.
[29]
ANTIEPILEPTICS in Plasma by LC-MS - Deuterated Internal Std - Code LC05110. 2018.
[30]
Deeb, S.; McKeown, D.A.; Torrance, H.J.; Wylie, F.M.; Logan, B.K.; Scott, K.S. Simultaneous analysis of 22 antiepileptic drugs in postmortem blood, serum and plasma using LC-MS-MS with a focus on their role in forensic cases. J. Anal. Toxicol., 2014, 38(8), 485-494.
[http://dx.doi.org/10.1093/jat/bku070] [PMID: 25217536]
[31]
Juenke, J.M.; Brown, P.I.; Urry, F.M.; Johnson-Davis, K.L.; McMillin, G.A. Simultaneous UPLC-MS/MS assay for the detection of the traditional antipsychotics haloperidol, fluphenazine, perphenazine, and thiothixene in serum and plasma. Clin. Chim. Acta, 2013, 423, 32-34.
[http://dx.doi.org/10.1016/j.cca.2013.04.014] [PMID: 23618971]
[32]
Tang, P. Determination of Posaconazole in Plasma/Serum by High-Performance Liquid Chromatography with Fluorescence Detection. Separations, 2017, 4(2), 16.
[http://dx.doi.org/10.3390/separations4020016]
[33]
Bioanalytical Method Validation Guidance for Industry. 2018.

© 2022 Bentham Science Publishers | Privacy Policy